The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca (LON:AZN) has had a rough month with its share price down 9.1%. But if you pay close attention, you ...

The AstraZeneca PLC ADR AZN inched 0.06% higher to $78.58 Wednesday, on what proved to be an all-around dismal trading ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other big name stocks.

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

AstraZeneca Plc has strong compliance policies in China and is working closely with authorities following the detention of ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short ...

AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...